Drugs / tigatuzumab
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01220999 | Oct 2010 → Jun 2012 | colorectal neoplasm | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1 | NCT01124630 | May 2010 → Jul 2013 | colorectal cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT00320827 | — | cancer, lymphoma | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT01307891 | Mar 2011 → Jun 2016 | triple-negative breast carcinoma | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT01033240 | Jul 2010 → Jul 2012 | hepatocellular carcinoma | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00945191 | Oct 2009 → Aug 2011 | ovarian carcinoma, uterine adnexa cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00969033 | Jul 2009 → Dec 2011 | colorectal cancer | Daiichi Sankyo | Terminated | No outcome recorded |
| Phase 2 | NCT00991796 | Jun 2009 → Jul 2011 | non-small cell lung carcinoma | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00521404 | Aug 2007 → Aug 2010 | malignant pancreatic neoplasm | Daiichi Sankyo | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tigatuzumab | “A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve...” PMID 24148258 ↗ Oct 20132“Tigatuzumab is a humanized monoclonal antibody that acts as a death receptor-5 agonist and exerts tumour necrosis factor-related apoptosis-inducing ligand-like activity.” PMID 26071796 ↗ Jun 2015 |
| Known as | Anti-dr5 moab | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743080 ↗ |
| Known as | Anti-trail-r2 moab | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743080 ↗ |
| Known as | CS-1008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00991796 ↗ |
| Known as | Tigatuzumab, CS-1008 | “Tigatuzumab, CS-1008” NCT01307891 ↗ |
| Known as | TRA-8 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743080 ↗ |
| Action | Activate | “Tumor necrosis factor receptor superfamily member 10B agonist” CHEMBL1743080 ↗1“agonistic antibody to human death receptor 5” PMID 26124477 ↗ Jun 2015 |
| Modality | Monoclonal antibody | “a Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)” NCT00320827 ↗ |
| Route | Intravenous | “CS-1008 intravenous (IV) infusion” NCT00945191 ↗ |
| Target | TNFRSF10B | “Tumor necrosis factor receptor superfamily member 10B agonist” CHEMBL1743080 ↗ |